US Population Eligibility and Estimated Impact of Semaglutide Treatment on Obesity Prevalence and Cardiovascular Disease Events

Overview of attention for article published in Cardiovascular Drugs and Therapy, August 2023

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
One of the highest-scoring outputs from this source (#1 of 772)
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (99th percentile)

Mentioned by

news: 47 news outlets
blogs: 4 blogs

twitter: 22 X users

Readers on

mendeley: 16 Mendeley

Summary News Blogs X

So far, Altmetric has seen 4 posts from 4 blogs.

Weight-Loss Drugs Ozempic and Wegovy Can Also Protect the Heart

Feed: All Latest, 05 Sep 2023

A new study shows that semaglutide reduces heart failure symptoms like fatigue and swelling by bringing down body weight.

Semaglutide Can Cut Prevalence of Obesity, CVD in Eligible U.S. Adults

Physician's Weekly, 23 Aug 2023

TUESDAY, Aug. 22, 2023 (HealthDay News) — Semaglutide treatment among eligible U.S. adults can reduce the prevalence of obesity…

Preventing Heart Attacks, Strokes, and Deaths by Treating Obesity

ConscienHealth, 21 Aug 2023

How much might the application of new insights from the SELECT study of treating obesity do for preventing heart attacks…

Almost 100 Million Americans Eligible For New Weight Loss Drug

Science Alert, 21 Aug 2023

The impact could be huge.

This page shows the most recent blog posts that mention this research output.

Click here to find out how to access more activity.